Prevention and treatment of synucleinopathic and amyloidogenic disease
AssigneesNeotope Biosciences Limited, The Regents of the University of California
InventorsDale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Claims15
A method of reducing the risk of, lessening the severity of, delaying the outset of or treating a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising
- administering to a patient having or at risk of the disease an effective regime of a monoclonal antibody that competes with antibody 6H7 deposited as ATCC PTA-6910 for specific binding to alpha synuclein and specifically binds to an epitope within residues 1-10 of human alpha-synuclein, residues being numbered according to SEQ ID NO:1.
A method of reducing the risk of, lessening the severity of, delaying the outset of or treating a disease characterized by Lewy bodies or alpha- synuclein aggregation in the brain, the method comprising
- administering to a patient having or at risk of the disease an effective regime of a first monoclonal antibody that competes with antibody 6H7 deposited as ATCC PTA-6910 for specific binding to alpha synuclein and specifically binds to an epitope within residues 1-10 of human alpha-synuclein, residues being numbered according to SEQ ID NO:1 and administering a second antibody that that specifically binds to an epitope within residues 100-140 of human alpha-synuclein.
Dependencies are inferred from the claim text.